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A B S T R A C T
Ischemic heart conditions are among the main causes of sudden cardiac death worldwide. One of the strategies
for avoiding myocardial infarction is the low-dose, prophylactic use of acetylsalicylic acid (ASA), an inhibitor of
platelet aggregation. To avoid the gastrointestinal damage, ASA prodrugs bearing nitric oxide (NO)-donating
moiety covalently conjugated to ASA have been synthesized and evaluated extensively worldwide. Herein the
synthesis of a new hybrid ASA ester covalently attached to the NO donor linsidomine, an active metabolite of
molsidomine (MOL) is reported. Cell viability assay and hemolysis tests were performed in H9c2 cells and rat
erythrocytes, respectively. Our new compound, the ERJ-500 not affected negatively the viability of living cells
in the concentration range of 100 nM to 100 μM. Using the ex vivo Langendorff method on hearts originated
from female rats, compound ERJ-500 displayed a dose-dependent, outwashable vasodilative effect in coronary
arteries. Vasodilation was observed on isolated working heart model as well, with elevated stroke volume in
hearts treated with ERJ-500. Furthermore, a decreased infarct size was also noticed in ERJ-500 treated hearts
after ischemia/reperfusion. Based on these observations it can be expected that our new hybrid ASA may
contribute to new pharmacological tool in the therapy of ischemic heart conditions and associated syndromes.
1. Introduction
Acetylsalicylic acid (ASA), also known as aspirin - the oldest non-
steroidal anti-inflammatory drug (NSAID) - is extensively used for the
treatment of pain and inflammation and because of its antithrombotic
properties, it is also commonly used for the prophylaxis against myo-
cardial infarction and stroke. The anti-inflammatory action of ASA is
based on the inhibition of cyclooxygenase (COX1 and COX2) enzymes
involved in prostaglandin (PG) biosynthesis (Catella-Lawson et al.,
2001b). However, ASA is a much more potent inhibitor of COX1 iso-
enzyme than that of COX2 (Meade et al., 1993). Moreover, ASA irre-
versibly inhibits COX1 in platelets, consequently resulting in the in-
hibition of thromboxane A2 biosynthesis (Catella-Lawson and Crofford,
2001). Since thromboxane A2 is a potent platelet aggregator and causes
vasoconstriction, this inhibitory process affects the antiplatelet-ag-
gregation property of ASA. Low-dose, long-term prophylactic use of
ASA is limited by its strong local irritant effects and gastrotoxicity
(Schoen and Vender, 1989; Wolfe et al., 1999) and ulcerative ability.
There is an increasing number of experimental data supporting basic
physiological and protective roles of nitrogen monoxide, also called
nitric oxide (NO), and nitrogen monoxide-releasing molecules
(NMRMs) in injured tissues (Abu-Amara et al., 2012; Garry et al., 2015;
Nagasaka et al., 2008; Phillips et al., 2009). The main source of en-
dogenous NO is nitrogen monoxide synthase (NOS). NOS/NO system
was proved to play an important role in signaling mechanisms and
several physiological processes, including the maintenance of neuronal
(Prast and Philippu, 2001), immune (Wink et al., 2011), and cardio-
vascular functions (Strijdom et al., 2009). Moreover, NO acts as a
crucial signaling molecule and an effector mediator to regulate the
coronary artery function in the myocardium (Bohlen, 2015). However,
overexpression of inducible NOS and its consequence, an extensive
increase in endogenous NO production may not be beneficial for the
myocardium (Csonka et al., 1999; Varga et al., 1999). On the other
hand, molecules releasing NO including molsidomine (MOL) are used as
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antihypertensive and antianginal drugs.
The strategy for avoiding the systemic gastrointestinal damage, ASA
prodrugs bearing nitrogen monoxide (NO)–donating moiety covalently
attached to the carboxylic function of ASA were designed since locally
released NO is able to trigger anti-inflammatory effects (MacNaughton
et al., 1989; Wallace, 2007). Nitrate ester (Gilmer et al., 2007;
Lazzarato et al., 2009; Rolando et al., 2013), furoxan (Cena et al.,
2003), or diazenium-diolate derivatives (Abdellatif et al., 2009;
Velazquez et al., 2005; Velazquez et al., 2008) have been attached
covalently to ASA to form ester-type prodrugs. The biological activity of
these hybrid aspirins has been evaluated extensively. Thus, nitrate ester
derivative NCX4016 prevented thromboembolism and restenosis and
protected the heart from ischemia/reperfusion injury in animal models
(Gresele and Momi, 2006) displaying no gastrotoxicity in the stomach.
Further beneficial effects include the inhibition of platelet COX1 acti-
vation and favorable influence on platelet-activation function in
healthy volunteers (Gresele and Momi, 2006). Additional advantageous
properties of ASA and NMRMs include anti-inflammatory and gastro-
sparing activities (Abdellatif et al., 2009; Cena et al., 2003; Lazzarato
et al., 2009; Rolando et al., 2013; Velazquez et al., 2005; Velazquez
et al., 2008). Furthermore, various NO donors have been developed as
pharmacological tools to induce the protective effect of the ischemic
myocardium (Ruiz-Hurtado et al., 2007). The NMRMs release NO into
biological systems for therapeutic purposes in a controlled and safe
manner (Burgaud et al., 2002). The cardiovascular effects of NMRMs
are currently under intensive investigation and various classes of
compounds are being developed with the goal of exploiting therapeutic
potentials in the treatment of inflammatory and cardiovascular diseases
(Bell et al., 2003; Ripamonti et al., 2017). Thus, it is quite rational to
hypothesize that an NMRM bearing ASA and molsidomine may have
vasoactive, and COX inhibitor activity. Acetylsalicylic acid and molsi-
domine are used as drugs for several decades. Therefore, their side ef-
fects and pharmacokinetics are well known. Moreover, molsidomine
excels from NO donor compounds since during long-term treatment
with it, tolerance development is not a clinically relevant problem
(Rudolph and Dirschinger, 1991).
2. Material and methods
2.1. Chemistry
MOL derivative 7 was prepared according to literature procedures
(Soulère et al., 2003). All reagents were purchased from commercial
suppliers and used without further purification. TLC was performed on
Kieselgel 60 F254 (Merck, Darmstadt, Germany) with detection by UV-
light (254 nm) and immersing into sulfuric acidic ammonium-mo-
libdenate solution followed by heating. Flash column chromatography
was performed on Silica gel 60 (Merck 0.040–0.063mm). Organic so-
lutions were dried over Na2SO4 or MgSO4 and concentrated in vacuum.
The 1H NMR (400MHz) and 13C NMR (101MHz) spectra were recorded
with a Bruker DRX-400 spectrometer at 25 °C. Chemical shifts are re-
ferenced to Me4Si (0.00 ppm for 1H) and to the residual solvent signals
(CDCl3: 77.1 for 13C). MALDI-TOF MS analyses of the compounds were
carried out in the positive reflectron mode using a BIFLEX III mass
spectrometer (Bruker, Karlsruhe, Germany) equipped with delayed-ion
extraction. 2,5-Dihydroxybenzoic acid (DHB) was used as matrix and
F3CCOONa as cationising agent in DMF.
2.1.1. Compound 5
Compound 4 (4.37 g, 10mmol) was dissolved in dry di-
chloromethane (50ml) and Et3N (2ml) was added to the stirred solu-
tion. Compound 3 (1.99 g, 10mmol) dissolved in dry dichloromethane
(10ml) was added dropwise at 0 °C to the reaction mixture and it was
stirred for 5 h at room temperature. The reaction mixture was quenched
with satd. aq. NaHCO3 (30ml), stirred for further 15min, then it was
diluted with dichloromethane (100ml) and extracted with 10%
NaHSO4 (30ml) and water (30ml), dried over Na2SO4, filtered and
evaporated at 35 °C in vacuum. The crude product was purified by flash
column chromatography (n-hexane:acetone 7:3) to give 5 as a pale
yellow syrup (4.0 g, 67%). Rf 0.34 (n-hexane:acetone 7:3);1H NMR
(400MHz, CDCl3): δ 8.03 (dd, J=7.8 Hz, J=1.8 Hz, 1H, arom), 7.53
(td, J=7.8 Hz, J=1.8 Hz, 1H, arom), 7.47–7.45 (m, 6H, arom),
7.30–7.19 (m, 10H, arom), 7.08 (dd, J=8.1 Hz, J=0.8 Hz, 1H),
4.41–4.39 (m, 2H, TEG-CH2), 3.78–3.76 (m, 2H, TEG-CH2), 3.70–3.65
(m, 10H, 5 x TEG-CH2), 3.23 (t, J=5.2 Hz, 2H, TEG-CH2), 2.34 (s, 3H,
CH3 Ac); 13C NMR (101MHz, CDCl3): δ 169.9 (1C, Cq Ac), 164.5 (1C
COO), 150.8 (1C, Cq arom), 144.2 (3C, Cq arom), 134.0, 132.0, 128.8,
127.9, 127.0, 126.1, 123.9 (19C, arom), 123.3 (1C, Cq arom), 86.6 (1C,
Cq Tr), 70.9, 70.8, 70.7, 69.2, 64.4, 63.4 (8C, 8 x TEG-CH2), 21.10 (1C,
CH3 Ac); MS (MALDI-TOF): m/z calcd for C36H38NaO8: 621.25
[M+Na]+; found: 621.32.
2.1.2. Compound 6
Compound 5 (1.2 g, 2.0mmol) was added to the mixture of hexa-
fluoroisopropanol (7.5 ml), BF3·Et2O (50 μl, 0.2 equiv.) and Et3SiH
(1.2ml, 3.8 equiv.). After complete conversion of the starting com-
pound (cc. 15min) the reaction was quenched with satd. aq. NaHCO3
solution (2ml). The mixture was concentrated in vacuum and the re-
sidue was purified by flash column chromatography (n-hexane:acetone
1:1) to give compound 6 as a colorless syrup (460mg, 65%). Rf 0.25 (n-
hexane:acetone 1:1); 1H NMR (400MHz, CDCl3): δ 8.05 (dd,
J=7.8 Hz, J=1.6 Hz, 1H, arom), 7.56 (td, J=7.9 Hz, J=1.6 Hz, 1H,
arom), 7.32 (td, J=7.6 Hz, J=1.2 Hz, 1H, arom), 7.11 (dd,
J=8.1 Hz, J=1.2 Hz, 1H, arom), 4.45–4.43 (m, 2H, TEG-CH2),
3.81–3.78 (m, 2H, TEG-CH2), 3.74–3.65 (m, 10H, 5 x TEG-CH2),
3.60–3.58 (m, 2H, TEG-CH2), 2.62 (s, 1H, TEG-OH), 2.36 (s, 3H, CH3
Ac); 13C NMR (101MHz, CDCl3): δ 169.9 (1C, Cq COO), 164.5 (1C, Cq
Ac), 150.8 (1C, Cq arom), 134.1, 132.0, 126.1, 123.9 (4C, arom), 123.2
(1C, Cq arom), 72.5, 70.8, 70.7, 70.6, 70.4, 69.2, 64.3, 61.8 (8C, 8 x
TEG-CH2), 21.1 (1C, CH3 Ac); MS (MALDI-TOF): m/z calcd for
C17H24NaO8: 379.36 [M+Na]+; found: 379.21.
2.1.3. Compound ERJ-500
The starting materials were dried over P2O5 overnight. Compound 7
(2.01 g, 6mmol) was suspended in dry acetonitrile (100ml) and com-
pound 6 (2.49 g, 7mmol) dissolved in dry acetonitrile (10ml) was
added. The reaction mixture was stirred at reflux temperature for 2 h,
then it was evaporated. The crude product was purified by flash column
chromatography (n-hexane: acetone 6:4→ 1:1) to give ERJ-500 as a
colorless syrup (758mg, 41%).
Rf 0.16 (CH2Cl2:acetone 8:2); 1H NMR (400MHz, CDCl3): δ 8.03
(dd, J=7.9 Hz, J=1.7 Hz, 1H, arom), 7.7 s1H, CH sydnone, 7.56
(ddd, J=8.1, 7.4, 1.8 Hz, 1H, arom), 7.31 (td, J=7.7 Hz, 1.1 Hz, 1H,
arom), 7.10 (dd, J=8.1 Hz, J=1.1 Hz, 1H, arom), 4.43–4.41 (m, 2H,
CH2 morpholine), 4.26–4.24 (m, 2H, CH2 morpholine), 3.94–3.92 (m,
4H, 2 x TEG-CH2), 3.80–3.78 (m, 2H, CH2 morpholine), 3.74–3.72 (m,
2H, CH2 morpholine), 3.68–3.63 (m, 8H, 4 x TEG-CH2), 3.51–3.49 (m,
4H, 2 x TEG-CH2), 2.35 (s, 3H, CH3 Ac); 13C NMR (101MHz, CDCl3): δ
174.2 (1C, Cq carbamate), 169.7 (1C, Cq COO), 164.4 (1C, Cq Ac), 161.2
(1C, Cq sydnone), 150.6 (1C, Cq arom), 133.8, 131.8, 125.9, 123.7 (4C,
arom), 123.2 (1C, Cq arom), 70.6, 70.5, 69.3, 69.0, 65.4, 64.6, 64.3,
54.6 (13C, 1 x sydnone-C, 4 x morpholine-CH2, 8 x TEG-CH2), 20.9 (1C,
CH3 Ac). MS (MALDI-TOF): m/z calcd for C24H32N4NaO11: 575.20
[M+Na]+; found: 575.31.
2.1.4. Oxidation by synthetic porphyrin and the chemical Fenton system
Two reactions were carried out to test the stability of ERJ-500
molecule under oxidative conditions, based on the method as reported
by Csepanyi et al. (Csepanyi et al., 2017) recently, with minor mod-
ifications as follows: 50 μl of ERJ-500 dissolved in acetonitrile was used
for synthetic porphyrin oxidation in 10mM concentration. 400 μl of
ERJ-500 in 2.5 mM concentration for the Fenton reaction. Samples
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were drawn at 1 h in the Fenton reactions prior to injecting them in-
stantly to the HPLC and further investigation. Reaction mixtures for
blank contained acetonitrile only without ERJ-500. The control mix-
tures contained no peroxide.
2.2. Biological characterization
2.2.1. Determination of cytotoxicity by MTT assay
Assessment of the cytotoxicity of the ERJ-500, ASA, and MOL on
cellular survival was accomplished using the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay based on the method
described by Csepanyi et al. (Csepanyi et al., 2017). Briefly, H9c2 cells
were treated with 100 nM, 1 μM, 10 μM, 100 μM of ERJ-500, 100 μM of
MOL, 100 μM of ASA and 1% H2O2 (positive control) containing
medium for 24 h on 96 well plates. Then, MTT solution was added to
the medium and incubated for 3.5 h at 37 °C. After eliminating the so-
lution from the cells, isopropanol was added and incubated for 0.5 h at
37 °C to dissolve the formazan aggregates. Absorbance was measured at
570 nm and 690 nm.
2.2.2. Animals
Female Sprague Dawley (SD) rats with an average weight of
248 ± 6 g were used in the present study. Animals were nutrified with
standard rodent chow pellets (R/M-Z+H, ssniff Spezialdiäten GmbH,
Soest, Germany) ad libitum with free access to water and kept at an
ambient temperature of 25 ± 2 °C, with a relative humidity of
55 ± 5%, and a 12-h light-dark cycle. All animals were treated ac-
cording to the “Principles of Laboratory Animal Care” formulated by
the National Society for Medical Research, and the “Guide for the Care
and Use of Laboratory Animals” prepared by the National Academy of
Sciences and published by the National Institutes of Health (NIH
Publication no. 86–23, revised in 1996). Breeding and handling of an-
imals were approved by the Institutional Animal Care and Use
Committee of the University of Debrecen, Debrecen, Hungary.
2.2.3. Determination of hemolytic activity
Hemolysis tests were performed as described by Roka et al. (Roka
et al., 2015) with some minor modifications. Rat blood samples were
collected to K3EDTA containing vacuum tubes (BD, Plymouth, UK) and
were treated with 100 nM, 1 μM, 10 μM, 100 μM ERJ-500, 100 μM of
MOL and the same concentration of ASA in phosphate buffered saline
(PBS). The percentage of hemolysis was expressed as the ratio of he-
moglobin in the supernatant of the different chemical solutions related
to the hemoglobin concentration after the complete hemolysis of ery-
throcytes in water.
2.2.4. Langendorff heart preparation and assessment of heart rate and
coronary flow
Rats were anesthetized with an intraperitoneal pentobarbital so-
dium injection (60mg/kg), with heparin as an anticoagulant (1000 U/
kg). Following the induction of deep anesthesia, chest cavities were
opened, hearts were excised and placed in ice-cold modified Krebs-
Henseleit bicarbonate (KHB) buffer (containing 118mM NaCl, 5.8mM
KCl, 1.8 mM CaCl2, 25mM NaHCO3, 0.36mM KH2PO4, 1.2 mM MgSO4,
and 5.0 mM glucose). After excision, aortas were cannulated and each
heart was perfused with modified KHB buffer at a filling pressure of
100 cm of water, using the “non-working” Langendorff mode for 5min
in order to flush blood out from the myocardium. The setup was as-
sembled with two buffer-chambers at the same constant pressure. The
one contained the KHB buffer only, the other contained ERJ-500 dis-
solved into the KHB buffer at different concentrations (1 μM, 10 μM,
30 μM, 100 μM). At the end of the washout period, baseline cardiac
parameters were registered, including coronary flow (CF) and heart rate
(HR), and the inflow was switched to serve the hearts from the chamber
containing ERJ-500 for 10min. Next, 10min of washout period, fol-
lowed by 10min of adding once more the ERJ-500 containing buffer. A
continuous pressure signal was recorded during the whole experiment
with the help of a pressure transducer (ADInstruments, PowerLab,
Castle Hill, Australia), which was calibrated before each experiment.
HR was calculated from the continuously recorded pressure signal. CF
was assessed by the time-collecting of the coronary effluent.
2.2.5. Isolated working heart preparation to assess cardiac parameters and
infarct size
To measure cardiac function, isolated working heart preparations
were carried out based on a previously described method by Czompa
et al. (Czompa et al., 2014) on Sprague Dawley female rats divided into
two groups n= 11 in the control group, n=6 in the treated group.
After completing the isolated working heart preparation procedure
followed by 10min washout period, we registered the baseline working
heart parameters such as aorta flow (Catella-Lawson et al., 2001a),
coronary flow (CF), aortic pressure (AOP), heart rate (HR) and deri-
vated aortic pressure (AOdP/dT). Cardiac output (CO) was calculated
by the sum of AF and CF and we got stroke volume (SV) by dividing the
CO with HR. In the treated group, ERJ-500 was added to the KHB buffer
by a dilution of a previously prepared stock solution, creating a 100 μM
concentration of ERJ-500 in the heart inflow. The molecule-containing
KHB buffer was presented after the washout and baseline registration
period for 5 mins, followed by a 30min ischemia followed by 90min
reperfusion. Results of AOP, AOdP/dT, CO and AF are included in a
Data in Brief article (Szőke et al., 2019).
To determine the degree of the infarcted area in the myocardium,
triphenyl tetrazolium chloride (TTC) staining was performed according
to a previously presented study by Czompa et al. (Czompa et al., 2018).
Briefly, following ischemia and reperfusion, 50ml of 1% TTC solution
was perfused through the myocardium. Then, hearts were frozen, sec-
tioned, digitalized and all heart sections were blotted dry and weighed.
Risked and infarcted areas were quantified by an open-source plani-
metry software Fiji (Schindelin et al., 2012). Percentage of the infarcted
area compared to the whole risked area of the myocardium is re-
presented on a bar chart.
2.2.6. Statistical analyses
All data are presented as the average magnitudes of each outcome in
a group± standard error of the mean (Csepanyi et al.). Statistical
analysis was performed using t-test or one- or two-way analysis of
variance (ANOVA), followed by Tukey's multiple comparisons test with
GraphPad Prism software for Windows (GraphPad Software Inc., La
Jolla, CA, USA). Probability values (p) < 0.05 were considered sta-
tistically significant.
3. Results and discussion
3.1. Chemistry
3.1.1. Design and synthesis of ERJ-500
Starting with a research program for the synthesis of new hybrid
ASA derivatives we turned our attention to molsidomine (1) (3-mor-
pholino-N-ethoxycarbonyl sydnonimine), which is a NO donor and used
as a coronary vasodilator (Mindlin de Aptecar et al., 1985) in patients
suffering from coronary artery diseases. Compound 1 displayed pro-
tective effect on indomethacin and ASA-induced gastric injury in rats
(Mourad et al., 2000). Moreover, molsidomine (MOL) has a significant
platelet antiaggregatory activity in vitro (Nishikawa et al., 1982). We
postulated that a hybrid derivative of ASA and MOL would exhibit
advantageous and synergistic effects of the two drugs, i.e. diminished
side effects of ASA and improved inhibition of platelet aggregation. The
mesoionic MOL is metabolized in the following way (Scheme 1) (Reden,
1990).
The active metabolite is 2 (linsidomine, SIN-1), therefore, we hy-
pothesized that its covalent conjugation to acetylsalicylic acid would
result in a NO donor hybrid ASA. For the linkage between ASA and
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Scheme 1. Metabolism of molsidomine (The carbamate moiety is highlighted in green).
Scheme 2. Synthesis of ASA-molsidomine hybrid with a hydrolysable ester linkage (highlighted in yellow) and the metabolically labile carbamate moiety (high-
lighted in green).
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compound 2, we designed a tetraethyleneglycol chain to improve the
water solubility of the product and a carbamate group, similar to that in
compound 1. It is assumed that the planned ASA-MOL conjugate could
serve as a NO donor with a similar mechanism to MOL, a drug already
used for pharmacotherapy. Our goals practically in the present study
were (i) to produce a new NO donor hybrid aspirin and (ii) to study its
toxic and vasodilator effects, in the highlight of coronary artery dilation
in the myocardium.
For the synthesis of ERJ-500, acetylsalicylic acid chloride 3
(Burgstahler et al., 1976) was reacted with mono-triphenylmethyl tet-
raethyleneglycol 4 (Pilkington-Miksa et al., 2008), obtaining the 5
ester. The trityl group was removed using a reagent cocktail (Kicsak
et al., 2016) resulting in compound 6, which was allowed to react with
linsidomine active carbamate ester 7 (Soulère et al., 2003) to give ERJ-
500, the desired hybrid ASA derivative (Scheme 2).
It is important to note that ERJ-500 proved to be stable after one-
year long storage at room temperature (NMR analysis showed no de-
gradation).
3.1.2. Oxidative stability assays
The oxidative stability of the ERJ-500 compound was assessed
utilizing two novel biomimetic model systems. In the first set of ex-
periments a synthetic porphyrin, Fe(III) meso-tetra(4-sulfonatophenyl)
porphine chloride was applied. The total ion chromatograms of the
control and ERJ-500 after oxidation by synthetic porphyrin were al-
most identical, therefore the ERJ-500 molecule was resistant against
simple oxidative conditions, which could possibly change the structure
of the molecule in another case.
The oxidation of the ERJ-500 was done by the classical Fenton re-
action as well. The reaction mixtures were analyzed by HPLC-MS/MS.
Based on the recorded spectra of the control and test samples it can be
concluded that the compound was stable under the applied conditions,
as the peaks on the chromatogram were not changed notably after 1 h
of oxidation compared to the control chromatogram. The obtained re-
sults were identical to the ones achieved by the synthetic porphyrin
oxidation, further confirming the stability of the new molecule under
simple oxidative conditions.
A sample chromatogram of each oxidative stability models men-
tioned above can be found in a Data in Brief article (Szőke et al., 2019).
3.2. Biological studies
3.2.1. Safety evaluation of ERJ-500
To assess the direct cytotoxic effects of ERJ-500, we carried out
MTT assays at different concentrations of the studied molecule, and its
two constituents, ASA and MOL in H9c2 cells. A slight decrement can be
seen in all treated groups compared to the control, but all treated
groups resulted in a significantly higher cell viability compared to the
positive control group, which was treated with 1% H2O2. No significant
differences can be observed between the groups treated by ERJ-500 or
other molecules studied (Fig. 1.A.), therefore, we may conclude that
ERJ-500 is an equally safe compound as the MOL or ASA.
To confirm our previously demonstrated cytotoxicity results, we
performed hemolytic activity studies in blood cells isolated from
Sprague Dawley rats. The hemolytic activity in rat erythrocytes at dif-
ferent concentrations of ERJ-500, ASA and MOL were significantly
lower compared to the positive control group (Fig. 1.B.). Samples of the
latter group received sterile water, which induced 100% hemolysis. No
significant differences can be observed among the groups treated by
ERJ-500, ASA, and MOL, respectively in hemolytic activities, which
further confirm that our aspirin derivative seems to be a safe com-
pound.
3.2.2. Vasoactive effects of ERJ-500
To study the vasoactive effects of the ERJ-500 in the myocardium,
the drug was dissolved in the perfusion buffer at a concentration rate of
1 μM to 100 μM, and isolated hearts were perfused. During Langendorff
perfusion, the ERJ-500 did not produce any incidence of ventricular
tachycardia or ventricular fibrillation. In addition, heart rate was not
significantly changed in comparison with the drug-free control group
(Fig. 2.A.). Coronary flow was significantly increased by about 50% in
the group treated with 100 μM ERJ-500 (Fig. 2.B.). During Langendorff
perfusion, the coronary flow is influenced by the heart rate, the per-
fusion pressure, and the coronary dimension. Since the perfusion
pressure used in the present study is constant and the heart rate is not
significantly altered, the increased coronary flow could be a result of
the coronary relaxation. Although in the present study, the concentra-
tion of NO was not directly measured, and it would be the subject of
another study, our results support the hypothesis that NO may originate
from the ASA-MOL compound (ERJ-500), since salicylic acid shows no
vasodilator activity in the myocardium (Andrieu et al., 1999; Saito
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Fig. 1. Safety evaluation of ERJ-500 A. Cytotoxicity test. The bar chart represents cell survival rates in percentage compared to the control group, which served by
the solvent only (phosphate buffered saline-PBS). ERJ-500100 nM - 100 μM; ASA 100 μM; MOL 100 μM; and 1% H2O2. Results are expressed as mean ± SEM.
n= 20–67 cells in each group. *p < 0.05 in comparison with the positive control group (Pos. control).
B. Hemolysis test. The bars represent hemolytic activity in percentage referring to the control group, which contained the solvent (PBS) only. ERJ-500100 nM –
100 μM, ASA 100 μM, MOL 100 μM. Results are expressed as mean ± SEM. n= 8–11 in each group. *p < 0.05 in comparison with the positive control (H2O) group
(Pos. control).
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et al., 2004).
Cardioprotective effects of ASA and salicylic acid related derivatives
can be attributed to affect the platelet activation related to cycloox-
ygenase enzyme activities (COX1 and COX2) and heat stress protein
expression in the diseased myocardium (Rao and Fareed, 2012; Wu
et al., 2015).
To further confirm vasoactive effects of ERJ-500 and to study any
possible beneficial effects of the compound on the mechanical activity
of the hearts, we tested the molecule on the isolated working heart
perfusion system as well, at a concentration, which seemed the most
advantageous previously. In the working heart perfusion, when other
mechanisms also involved to compensate measurable vasoactive effects,
coronary flow was still significantly elevated in treated hearts with
100 μM ERJ-500 (Fig. 2.D.). Stroke volume was also significantly in-
creased, thus, ERJ-500 can be an additive effect to improve myocardial
contraction force (Fig. 2.E.). As previously measured in Langendorff
heart preparation, heart rate did not change notably in working heart
preparation also (Fig. 2.C.). Rest of the measured, non-significant
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Fig. 2. Effects of ERJ-500 on cardiac functions of isolated Langendorff and working heart.
A., Alteration of heart rate and B., coronary flow in the presence of the ERJ-500 at different concentrations (1–100 μM) when the heart is mounted on the
“Langendorff” apparatus. *p < 0.05 control vs. 100 μM; #p < 0.05 control vs. 30 μM; †p < 0.05 control vs. 10 μM. n=5 in each group.
C., Alteration of heart rate, D., coronary flow, and E., stroke volume in the presence (ERJ-500) or the absence (Control) of 100 μM ERJ-500, when the heart is
mounted on the isolated working heart apparatus. No significant differences were observed among groups. *p < 0.05 in comparison with the control values. n=11
in the control group, n=6 in the treated group.
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myocardial parameters can be found in a Data in Brief article (Szőke
et al., 2019).
3.2.3. Anti-ischemic effect of ERJ-500
To further analyze the effect of ERJ-500 on the rat myocardium,
infarct size was evaluated using the triphenyl-tetrazolium-chloride-
staining method (TTC). Following 30min of ischemia and 90min re-
perfusion, infarct zones of TTC-stained hearts were expressed in a
percentage of the whole myocardium. Fig. 3. shows that hearts perfused
with ERJ-500 containing buffer resulted in a significantly decreased
infarct size.
This result indicates that ERJ-500 has a cardioprotective effect,
which could be a consequence of the vasorelaxant property, however,
other mechanisms may also contribute to this effect.
4. Conclusion
In the present study, an attempt was made to synthesize a new NO-
releasing ASA derivative and ascertain whether the release of NO from
the MOL conjugate could be associated with enhanced myocardial
circulation, and consequently, giving a chance to the survival of cardiac
cells and tissues by preserving the oxygen supply via the dilation of
coronary vessels.
Based on our observations, the new molecule ERJ-500 appears to be
nontoxic and stable under oxidative conditions. Furthermore, our
pharmacological studies indicate vasoactive and anti-ischemic proper-
ties for the molecule. However, further in vivo studies are needed to
investigate the effect on whole organism.
5. Limitation of the study
The limitation of the study is the lack of direct measurement of NO
release from ERJ-500. However, since in small concentrations of ERJ-
500 a significant vasodilatation was observed, the authors believe that
it could be the result of NO release from ERJ-500.
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